SUMMARY The presence of complement-fixing antibody to an early herpes simplex virus type 2 (HSV-2) antigen (the AG-4 antigen) was correlated with HSV-2 infection in the sera of patients with genital herpes. Eighty-eight per cent of sera taken two weeks after clinical diagnosis of a primary or recurrent herpes infection in patients, confirmed to have HSV-2 by virus isolation and typing, contained the anti-AG-4 complement-fixing antibody. None of the patients with genital HSV-1 had the antibody, and only 9% of controls or patients with facial HSV-1 infection had positive results for the antibody. This correlation was used to identify genital HSV-2 infections when either no virus sample had been taken or when virus isolations had been unsuccessful. Thus, a simple complement-fixation test can confirm an HSV-2 virus infection without isolation of the virus from the herpetic lesion.
Introduction
Two types of herpes simplex virus have been isolated from genital lesions. While herpes simplex type 2 (HSV-2) is the type most commonly found in ulcerative genital lesions (ranging from 60% to 90% depending on the population under study)' 2 herpes simplex type 1 (HSV-1) has also been identified in genital lesions.' 2 Isolation of the herpes simplex virus from the lesion is usually followed by typing by a variety of different methods, such as virus neutralisation,3 immunoperoxidase methods,4 thymidine kinase induction,2 plaque morphology,5 DNA restriction endonuclease analysis,6 and others.7
The unequivocal identification of HSV-2 type antibody in patients' sera has been difficult because of the cross-reaction between HSV-1 and HSV-2 antibody and the high incidence of antibody to 
Results

TIME OF ANTIBODY DETECTION
The time-course appearance of complement-fixing antibody to AG-4 in recurrent HSV-2 and in primary HSV-1 and HSV-2 infections in patients with genital herpes is shown in the figure. Over the five-week period no anti-AG-4 complement-fixing antibody was detected in the patients with genital HSV-1 infections. The antibody was usually detected two weeks after a primary infection of HSV-2 and was still present five weeks later. On the other hand, in 12 . In the genital HSV-1 infections no antibody was detected and in both the patients with facial HSV-1 and the controls only 9lo of sera contained the antibody. Occasionally swabs from the herpes-like lesions yielded a virus that was not typed as herpes simplex and these patients did not have the antibody. When sera were taken from patients with genital herpes-like lesions, and no isolation of virus attempted, 82% contained anti-AG-4 complementfixing antibody. The anti-AG-4 antibody titres were compared with the virus typing data only after the former were known.
If a similar extract of HEP-2 cells infected with HSV-1 for four hours (similar to the AG-4 preparation-that is, multiplicity of infection at 0 7 pfu/cell) was used in the test no complement fixation was detected with sera from patients with either HSV-2 or HSV-1 infections. If the HSV-1 M Arsenakis and J T May infection rate was greater than 3 pfu/cell or the infection was allowed to proceed for 18 hours rather than four hours, however, most of the 14 days' HSV-2 sera (approximately 9007) would react with the HSV-1 extract in the complement-fixation test. This was probably because of the cross-reaction of HSV-1 antibody (HSV-neutralising antibody increases by twofold or threefold after infection") with the late HSV-1 antigens.
Discussion
We have found that the antigen that patients with HSV-2 infections react to in HSV-2 four-hourinfected HEP-2 cells is an immediate early protein of 160 000 molecular weight." This antigen has previously been used to detect anti-AG-4 complement-fixing antibodies in patients with cancer of the cervix.'0 12 We have found that it would also detect AG-4 antibodies in patients infected with HSV-2'0 "1 but not in those infected with HSV-1.°D etection of the anti-AG-4 complement-fixing antibody in HSV-2 patients is, however, dependent on the time at which the sera are taken after recurrence or primary herpetic infection (figure). When sera are taken 14 days after the appearance of the herpes-like lesion, or sometimes earlier in recurrent episodes, this simple complement-fixation test can detect whether the lesion is due to either HSV-2 or HSV-1. Sera taken at the time of presentation with HSV-2 lesions were positive for the antibody only in some recurrent cases, but once the antibody appeared (in most cases) it was found to persist for six months. " Decline in the antibody titres has been found as early as four weeks" and in other recurrent cases it has persisted for at least 18 months. Thus it is possible in most cases to repeat or perform the complement-fixation test more than two weeks after the appearance of lesions.
Our results suggest that the sera of 8807o of the patients with HSV-2 infections (diagnosed by virus isolation and typing by a neutralisation method) 
